• Ensoma

  Participated · Equity · Sep 2025

  Ensoma is a Boston-based biotechnology company focused on engineering hematopoietic stem cells directly inside the body to create durable genetic medicines for genetic diseases, immune disorders, and cancer. Its platform uses high-capacity virus-like particles (VLPs) that selectively target HSCs and can deliver up to 35 kb of genetic cargo, enabling single-base edits through large multi-gene insertions. The company combines these VLPs with proprietary base-editing and gene-integration systems, aiming for one-time intravenous administration. Proceeds from its latest financing will fund a Phase 1/2 clinical trial of lead candidate EN-374 for X-linked chronic granulomatous disease and support platform expansion into immuno-oncology and sickle cell programs. Ensoma’s strategy centers on creating off-the-shelf, non-myeloablative treatments that avoid the complexity and cost of ex vivo cell processing. The firm’s board now includes a Gilead appointee following the strategic investment. No financial metrics or commercial revenues have been disclosed to date.

• Inari

  Participated · Equity · Jan 2025

  Inari develops seed technologies that combine AI-powered predictive design with a multiplex gene editing toolbox to deliver step-change soybean, corn and wheat products. The company is singularly focused on seed technology for large-acre crops and operates an asset-light business model intended to support, not rival, seed companies. Inari reports strong performance from its first-generation products and progress toward commercialization, generating interest from seed companies both within and outside the U.S. Financially, the company completed a $144 million fundraise and has cumulative equity raised of more than $720 million. Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium, and employs more than 300 people. The new capital is intended to underpin long-term growth as Inari works to bring high-performing products to market at global scale. Inari develops seeds aimed at a more sustainable, nature‑positive food system by combining AI‑powered predictive design with a multiplex gene‑editing toolbox. The company intends to use the new funds to further advance its technology platform and accelerate product commercialization. Inari has a team of more than 300 employees and is led by CEO Ponsi Trivisvavet. Founded by Flagship Pioneering in 2016, the company is based in Cambridge, MA, with additional sites in West Lafayette, Ind., and Ghent, Belgium. The business recently closed a $103M funding round, bringing its total capital raised to $575M. Inari pairs AI-powered predictive design with multiplex gene editing to engineer seeds for the commercial agriculture market. The company focuses on multiplex gene-edited seed technology and advancing product development to deliver new value to growers and supply chains. It plans to use the new capital to further its technology position and expand product development efforts. Inari completed a $124M Series E equity raise and also refinanced and upsized a loan agreement to access up to $60M in debt capital. Led by CEO Ponsi Trivisvavet, the company was founded by Flagship Pioneering and has grown to more than 230 employees. Inari is based in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium. Inari has developed a platform that uses predictive design and artificial intelligence to build deep understanding of genes and to design blueprints for combinations of gene‑editing tools that enable multiple edits within a single genome. Those edits produce seeds that aim to increase crop yield while reducing agriculture's footprint. The company focuses on product development for corn and soybeans in North and South America and plans to use the new funds to accelerate advancements across its science platform and product development. Inari raised $208M in a Series D that brought its cumulative equity raised to more than $352M. The round was co‑led by Flagship Pioneering with participation from Alexandria Venture Investments, Investment Corporation of Dubai, Banque Pictet (on behalf of clients), Rivas Capital, and new investors G Squared and Pavilion Capital. Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Massachusetts, with additional sites in West Lafayette, Indiana, and Ghent, Belgium. The company is led by CEO Ponsi Trivisvavet and has a team of more than 180 employees. Inari develops next-generation seeds using genetic technologies and data science. Led by CEO Ponsi Trivisvavet, the company focuses on gene-edited crops designed to reduce the natural resources required to grow food. It intends to use recent capital to accelerate development and commercialization of those gene-edited crops. The company was founded by Flagship Pioneering in 2016. Inari is headquartered in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium. The company recently completed an $89M equity raise and has secured a $45M loan facility to support its plans.

• Cellarity

  Participated · Series C · Oct 2022

  Cellarity applies single-cell technologies and proprietary deep learning models to identify cellular drivers of disease and design drugs against the cellular signature. The company links biology and chemistry with high-dimensional transcriptomic data to create medicines that target whole-cell dysfunction rather than single molecular targets. Founded by Flagship Pioneering in 2017 and based in Somerville, Mass., Cellarity has developed capabilities to unravel complex disease biology and reveal new biology for drug creation. The company reports compounds validated in vitro and in vivo, including in higher species, and has ongoing programs in metabolic disease, hematology, and immuno-oncology. Cellarity plans to use recent financing proceeds to grow its talent base, strengthen its platform, and advance its pipeline toward the clinic. To date the company has raised $274 million in total funding. Cellarity is a Cambridge, Mass.-based life sciences company founded in 2017 within Flagship Labs. It is developing a new method of drug discovery that targets the cell rather than a single molecular target. The company combines system and network biology, high-resolution data and machine learning to unlock treatments across multiple therapeutic areas. Cellarity is led by Fabrice Chouraqui, who serves as CEO of Cellarity and is a CEO-Partner at Flagship Pioneering. In February 2021 the company raised $123M in a Series B financing. The funds will support its platform and drug discovery efforts across its stated therapeutic focus areas.

• Tessera Therapeutics

  Participated · Series C · Apr 2022

  Tessera Therapeutics has built a GENE WRITING platform that programs Mobile Genetic Elements to write and rewrite DNA in human cells. The platform can change any base pair to any other, make small insertions or deletions, and write entire genes into the genome using delivery of only RNA. Tessera has evaluated and engineered tens of thousands of natural and synthetic MGEs and further optimizes candidates for efficiency, specificity, and fidelity. The company positions GENE WRITING as a distinct approach from nuclease-based editing (e.g., CRISPR) with potential applications across genetic diseases, cancer, and preventive medicines. Tessera says the technology could enable curative, scalable, and easily administered genetic medicines both in vivo and ex vivo. Financially, the company announced it raised over $300 million in a Series C to advance the platform and its mission of curing disease by writing in the code of life. Tessera Therapeutics, founded by Flagship Pioneering and unveiled in July 2020, is developing a platform called Gene Writing that can change base pairs, make small insertions or deletions, and write entire genes into the genome. The company says its platform can engineer somatic genomes without double-stranded breaks and with minimal reliance on host DNA repair, permanently add new DNA to dividing cells, and deliver new sequences using only RNA. Tessera positions Gene Writing as a distinct approach that overcomes limits of nuclease-based gene editing and AAV-based gene therapy. The technology is intended to expand the range of diseases tractable by genetic approaches, including cardiovascular, oncological, neurodegenerative, and infectious diseases. Tessera plans to use new capital to accelerate research and development, expand its team, and build manufacturing and automation capabilities to advance multiple therapeutic programs toward clinical development.

• Catalog

  Led · Series B · Sep 2021

  Catalog is a Boston startup founded in 2016 by MIT scientists, including CEO Hyunjun Park, building a synthetic DNA-powered data storage and computing platform. Its proprietary data-encoding scheme minimizes de novo DNA synthesis to enable practical DNA-based information storage and computation. Catalog’s custom DNA writer, Shannon, is designed to write over 10MB/sec and can store up to 1.63TB of compressed data in a single run. The platform enables data management, computation, and automation, and Catalog plans to invest in computation functions over the next two to three years. The company expects to commercialize the platform around 2025 and will continue supporting collaborators and partners in the DNA ecosystem. Catalog is a member of the DNA Storage Alliance, works with about a dozen co-development partners in the U.S. and Europe, and recently opened an office in Seoul for Asia expansion. Expected applications include fraud detection, image processing for defect discovery in manufacturing, and digital signal processing such as seismic processing. Catalog develops a DNA-based platform for large-scale digital data storage and computation. Its core product is a custom-developed DNA writer and storage system called Shannon that writes at over 10 Mb/sec, generates over a trillion identifiers in a single run, and can store up to 1.63 Tb of compressed data per run. The company converts binary data into combinations of pre-synthesized DNA molecules using technology similar to inkjet printers, developed in collaboration with Cambridge Consultants. Catalog says its approach can hold a million times more data in the same volume as magnetic and solid-state media. Founded in 2016 by MIT scientists and led by CEO and co-founder Hyunjun Park and newly appointed CTO Dave Turek, the company plans to use new funding for early product trials and continued research and development. Catalog has raised $21M to date, including the $10M Series A announced in this round. Catalog is developing commercially viable DNA data storage technology and is based in Boston, MA, operating out of the Harvard Life Lab. The company’s first-generation commercial product will provide an online interface through which customers submit data; Catalog will write that data into DNA using the company’s machine. Once written into DNA, the material can be stored by Catalog or at the customer’s own facility (for example in a commercial refrigerator). Catalog is focusing its initial commercial pilots on organizations in government (including intelligence and space), IT, entertainment, and other sectors. Founders include MIT scientists Hyunjun Park (CEO) and Nathaniel Roquet, and Devin Leake serves as Chief Science Officer. While developing the technology the team consulted with Eric Shaqfeh (Stanford) and David Weitz (Harvard). The company has raised $9M in funding.

No current team members are available.